Literature DB >> 32440583

Risk of Bias in Randomized Clinical Trials on Psychological Therapies for Post-Traumatic Stress Disorder in Adults.

Juliana Martins Scalabrin1, Marcelo F Mello1, Walter Swardfager2,3, Hugo Cogo-Moreira1.   

Abstract

OBJECTIVE: To evaluate the factorial validity and internal consistency of a measurement model underlying risk of bias as endorsed by Cochrane for use in systematic reviews; more specifically, how the risk of bias tool behaves in the context of studies on psychological therapies used for treatment of post-traumatic stress disorder in adults.
METHODS: We applied confirmatory factor analysis to a systematic review containing 70 clinical trials entitled "Psychological Therapies for Chronic Post-Traumatic Stress Disorder in Adults" under a Bayesian estimator. Seven observed categorical risk of bias items (answered categorically as low, unclear, or high risk of bias) were collected from the systematic review.
RESULTS: A unidimensional model for the Cochrane risk of bias tool items returned poor fit indices and low factor loadings, indicating questionable validity and internal consistency.
CONCLUSION: Although the present evidence is restricted to psychological interventions for post-traumatic stress disorder, it demonstrates that the way risk of bias has been measured in this context may not be adequate. More broadly, the results suggest the importance of testing the risk of bias tool, and the possibility of rethinking the methods used to assess risk of bias in systematic reviews and meta-analyses.
© The Author(s) 2018.

Entities:  

Keywords:  post-traumatic stress disorder; psychometrics; psychotherapy; scale evaluation

Year:  2018        PMID: 32440583      PMCID: PMC7219943          DOI: 10.1177/2470547018779066

Source DB:  PubMed          Journal:  Chronic Stress (Thousand Oaks)        ISSN: 2470-5470


  12 in total

Review 1.  [Pharmacological treatment of posttraumatic stress disorder].

Authors:  Márcio Bernik; Marcionilo Laranjeiras; Fábio Corregiari
Journal:  Braz J Psychiatry       Date:  2003-06       Impact factor: 2.697

2.  Reliability of the PEDro scale for rating quality of randomized controlled trials.

Authors:  Christopher G Maher; Catherine Sherrington; Robert D Herbert; Anne M Moseley; Mark Elkins
Journal:  Phys Ther       Date:  2003-08

3.  Is More Ever Too Much? The Number of Indicators per Factor in Confirmatory Factor Analysis.

Authors:  H W Marsh; K T Hau; J R Balla; D Grayson
Journal:  Multivariate Behav Res       Date:  1998-04-01       Impact factor: 5.923

4.  Reporting Results from Structural Equation Modeling Analyses in Archives of Scientific Psychology.

Authors:  Rick H Hoyle; Jennifer C Isherwood
Journal:  Arch Sci Psychol       Date:  2013-02

5.  Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Authors:  A R Jadad; R A Moore; D Carroll; C Jenkinson; D J Reynolds; D J Gavaghan; H J McQuay
Journal:  Control Clin Trials       Date:  1996-02

6.  Bayesian structural equation modeling: a more flexible representation of substantive theory.

Authors:  Bengt Muthén; Tihomir Asparouhov
Journal:  Psychol Methods       Date:  2012-09

7.  From alpha to omega: a practical solution to the pervasive problem of internal consistency estimation.

Authors:  Thomas J Dunn; Thom Baguley; Vivienne Brunsden
Journal:  Br J Psychol       Date:  2013-08-06

Review 8.  Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults.

Authors:  Jonathan I Bisson; Neil P Roberts; Martin Andrew; Rosalind Cooper; Catrin Lewis
Journal:  Cochrane Database Syst Rev       Date:  2013-12-13

Review 9.  Sports and games for post-traumatic stress disorder (PTSD).

Authors:  Sue Lawrence; Mary De Silva; Robert Henley
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

10.  Assessing Risk of Bias in Randomized Controlled Trials for Autism Spectrum Disorder.

Authors:  Paola Matiko Martins Okuda; Cheryl Klaiman; Jessica Bradshaw; Morganne Reid; Hugo Cogo-Moreira
Journal:  Front Psychiatry       Date:  2017-11-29       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.